On March 5, 2021, a nurse was vaccinated against Coronavirus disease (COVID-19) at the East Valley Community Health Center in Lapuente, California.
Lucy Nicholson | Reuters
Modana According to early data released in the company’s first quarter financial results, the company’s Covid-19 vaccine is 96% effective for children aged 12 to 17 years.
The young biotechnology company also said it plans to submit data on adult vaccines to the FDA for full approval later this month. The successful sale of the Covid-19 vaccine helped drive Moderna’s first quarter profits.
According to an average estimate compiled by Refinitiv, Moderna compared what Wall Street expected:
- EPS: $ 2.84 per share vs. expected $ 2.39 per share
- Revenue: $ 1.94 billion compared to expected $ 2.03 billion
According to the revenue report, Moderna’s Covid-19 vaccine had sales of $ 1.7 billion.
The company’s stock fell more than 6% in pre-market transactions.A strain of Covid vaccine maker put into a tank after the Biden administration said it late Wednesday Supports waiver of patent protection About the Covid vaccine, citing the global health crisis.
Moderna has raised its 2021 sales forecast for vaccines from the previous $ 18.4 billion forecast to $ 19.2 billion. Earlier this week, rival Pfizer also raised its vaccine sales forecast, forecasting full-year sales of $ 26 billion.
According to the company, R & D spending this quarter was $ 401 million, compared to $ 115 million in the year-ago quarter.
“In the first quarter, the Moderna team fulfilled its supply promises to many governments and helped protect more than 100 million people,” Moderna CEO Stephane Bancel said in a press release. “This achievement marks the first profitable quarter in the company’s history after a decade of scientific innovation and billions of dollars invested in enabling an mRNA platform.”
Founded in 2010, Moderna is the second company to obtain US approval for the Covid vaccine after Pfizer. Since the vaccine needs to be given twice every four weeks, the US government has agreed that there are enough 300 million doses to inoculate 150 million Americans.
Mr Bansel said Thursday that the company is “actively involved” in 2022 discussions and agreements with all governments currently supplying in 2021.
On wednesday, the company Announcement Booster shots of the vaccine produced a promising immune response against the first identified B.1.351 and P.1 variants in South Africa and Brazil, respectively. The data is tentative and has not yet been peer reviewed.
“New variations of concern continue to emerge around the world,” Bansel told analysts. As the Southern Hemisphere enters fall and winter, more variations of concern may emerge in the next six months. I think there is. ” “I believe we will need booster shots because we believe the virus will never go away.”
On Wednesday, the company released promising preliminary data on booster shots designed to protect against the first identified B.1.351 and P.1 variants in South Africa and Brazil. Previously vaccinated adult booster doses were found to increase the neutralizing antibody response to the original virus and the two mutants. Scientists say it is more contagious than the original Covid-19 strain.
As a teenager, Moderna said Thursday that the original vaccine was generally well tolerated and no serious safety concerns had been identified so far. The study was attended by more than 3,000 participants between the ages of 12 and 17.
The new data says that pharmaceutical companies and scientists may need booster shots of the Covid-19 vaccine and, in some cases, additional shots each year, as in the case of seasonal flu. Provided.
This is a developing story. Check for updates.
Correction: This article has been updated to correct 2010, the year the company was founded.
According to Moderna, early data show that the Covid vaccine is 96% effective in teens.
Source link According to Moderna, early data show that the Covid vaccine is 96% effective in teens.